Clinical trial
A Phase 2a Study to Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Cabozantinib in Patients With Localized Clear Cell Renal Cancer.
NCT05127824 is registered in ClinicalTrials.gov with Jodi Maranchie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study to Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Cabozantinib in Patients With Localized Clear Cell Renal Cancer.
- Lead sponsor
- Jodi Maranchie
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 6, 2023
- Completion date
- December 31, 2027
- Enrollment
- 42 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.